2 Dividend Stocks Defying the Market Dip to Buy for a Lifetime of Passive Income
Equities haven't performed well this year due to a combination of factors. Macroeconomic tensions are at the top of that list. Still, some companies are doing just fine amid the volatility, including AbbVie (NYSE: ABBV) and Abbott Laboratories (NYSE: ABT). These two healthcare leaders may or may not continue beating the market in the next few weeks -- it's challenging to predict the direction of any single stock or the broader equities in such a short period.However, no matter what happens in the near term, AbbVie and Abbott Laboratories are excellent long-term picks for dividend-focused investors. Here's why.AbbVie's shares dropped off a cliff in November after it announced a clinical setback for emraclidine, an investigational schizophrenia treatment it got in an $8.7 billion acquisition. Investors were worried the company spent nearly $9 billion for nothing, which is understandable. Continue reading
Equities haven't performed well this year due to a combination of factors. Macroeconomic tensions are at the top of that list. Still, some companies are doing just fine amid the volatility, including AbbVie (NYSE: ABBV) and Abbott Laboratories (NYSE: ABT). These two healthcare leaders may or may not continue beating the market in the next few weeks -- it's challenging to predict the direction of any single stock or the broader equities in such a short period.
However, no matter what happens in the near term, AbbVie and Abbott Laboratories are excellent long-term picks for dividend-focused investors. Here's why.
AbbVie's shares dropped off a cliff in November after it announced a clinical setback for emraclidine, an investigational schizophrenia treatment it got in an $8.7 billion acquisition. Investors were worried the company spent nearly $9 billion for nothing, which is understandable.
